Blog
RSS FeedPosted by Michael Wonder on 16 Jun 2018
ICER report questions the adequacy of evidence on overall health benefit of elagolix given limitations of information on safety and limited evidence comparing to other treatment options
15 June 2018 - The emerging drug may be cost-effective compared to no treatment if priced in line with analyst ...
Posted by Michael Wonder on 12 Jun 2018
ICER's updated assessment of new targeted therapies for plaque psoriasis notes minor distinctions in effectiveness, while recent price hikes have made entire drug class less cost-effective
12 June 2018 - Value-based price benchmarks for new IL-23 agents range from $25,000-$42,000 per year, which would require a discount ...
Posted by Michael Wonder on 07 Jun 2018
ICER's final report on CFTR modulators for cystic fibrosis calls for manufacturer restraint and increased transparency in pricing decisions
7 June 2018 - Pricing overreach harms people with cystic fibrosis and threatens the health care system's ability to support future ...
Posted by Michael Wonder on 31 May 2018
ICER finds price of erenumab aligns with clinical benefit in patients for whom other therapies have failed to prevent migraines
31 May 2018 - Clinical benefits similar to other new CGRP inhibitors included in review. ...
Posted by Michael Wonder on 15 May 2018
ICER posts draft scoping document on biologic treatments for asthma
15 May 2018 - Document open to public comment until 5 June 2018. ...
Posted by Michael Wonder on 15 May 2018
Americans thought they would get a PHARMAC from Trump
15 May 2018 - If New Zealand was showing any interest in a bilateral trade agreement with the United States, ...
Posted by Michael Wonder on 09 May 2018
Evaluating and valuing drugs for rare conditions: no easy answers
9 May 2018 - We find ourselves in an era of unprecedented growth in the development and use of so-called “orphan” ...
Posted by Michael Wonder on 05 May 2018
Watchdog says Vertex cystic fibrosis drugs are not cost effective, but company calls analysis a ‘sham’
4 May 2018 - The oldest Vertex drug for cystic fibrosis, Kalydeco, lists for $311,000, while the newer treatment Orkambi lists ...
Posted by Michael Wonder on 05 May 2018
ICER releases draft evidence report on elagolix for endometriosis
4 May 2018 - Public comment period now open until 31 May; requests to make oral comment during public meeting also ...
Posted by Michael Wonder on 04 May 2018
ICER finds that at current prices CFTR modulators for cystic fibrosis improve patient outcomes at costs that far exceed standard cost-effectiveness levels
3 May 2018 - Evidence report findings and contextual factors related to treatments for ultra-rare disorders such as cystic fibrosis ...
Posted by Michael Wonder on 27 Apr 2018
ICER releases draft condition update report on treatments for plaque psoriasis
27 April 2018 - Public comment period now open until 25 May; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 27 Apr 2018
ICER posts draft scoping document on medication-assisted treatments for opioid use disorder
26 April 2018 - Document open to public comment until 16 May 2018; report expected to review buprenorphine implant, extended-release ...
Posted by Michael Wonder on 24 Apr 2018
Institute for Clinical and Economic Review to assess biologic treatments for asthma in upcoming assessment
24 April 2018 - Report will be subject of November Midwest CEPAC meeting; open input now being accepted until 10 ...
Posted by Michael Wonder on 16 Apr 2018
ICER's final report on emicizumab shows new treatment improves health while lowering costs for certain people with haemophilia A
16 April 2018 - Report also highlights need for future pricing of haemophilia treatments that allows for "shared savings" between innovators ...
Posted by Michael Wonder on 12 Apr 2018
ICER posts draft scoping document on therapies for prevention of hereditary angioedema attacks
12 April 2018 - Document open to public comment until 2 May 2018; report expected to review lanadelumab (Shire), and C1 ...